NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

文章核心观点 临床阶段免疫肿瘤公司Portage Biotech公布2025财年（截至3月31日）财务结果，净亏损大幅减少，运营费用降低，主要因非现金损失减少和研发、行政费用下降 [1][2][3] 财务结果 净亏损 - 2025财年净亏损约680万美元，含约20万美元非现金费用，较2024财年约7540万美元净亏损减少约6860万美元，主要因2024年3月31日公司无形资产、商誉和部分投资全额减值致非现金损失降低 [2] 运营费用 - 2025财年运营费用740万美元，低于2024财年1820万美元，减少1080万美元 [3] 研发费用 - 2025财年研发费用约310万美元，较2024财年约1250万美元减少约940万美元，降幅约75%，主要因临床试验成本、制造相关成本、非现金股份薪酬费用、工资相关费用、研发服务和科学咨询费减少，以及2024年一次性里程碑付款和iNKT研究过渡费用 [4] 行政费用 - 2025财年行政费用约430万美元，较2024财年约570万美元减少约140万美元，降幅约24.9%，主要因非现金股份薪酬费用、专业费用、董事费用和办公用品费用减少，部分被工资和咨询费用增加抵消 [5] 税前收支 - 2025财年税前收支净收益约60万美元，主要因iOx与Parexel主服务协议义务和负债结算获90万美元净收益，部分被认股权证公允价值变动40万美元非现金损失抵消；2024财年净亏损约6770万美元，主要因iOx和Tarus在研研发项目全额减值及对Stimunity投资和可转换票据减值 [6][7] 递延所得税 - 2024财年非现金递延所得税净收益1050万美元，2025财年仅3000美元，2024年收益主要因iOx在研研发项目非现金减值损失的税收影响，部分被前期确认损失转回抵消 [8] 现金与负债 - 截至2025年3月31日，公司现金及现金等价物约170万美元，流动负债约110万美元 [9] 综合运营与财务报表 运营报表 - 2025财年研发费用312.9万美元，行政费用425.4万美元，运营亏损738.3万美元；2024财年研发费用1253.5万美元，行政费用566.4万美元，运营亏损1819.9万美元 [13] 财务状况表 - 2025年3月31日，公司总资产222.5万美元，其中流动资产222.5万美元，流动负债110万美元；2024年总资产777.9万美元，流动资产769.5万美元，流动负债287.9万美元 [16][17]

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial. Webcast and Conference Call Information The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8 ...

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpointInidascamine continues to exhibit a favorable safety and tolerability profileFull data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on ...

TORONTO and HAIFA, Israel, July 25, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that the Falling Walls Foundation has named the Company a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. NurExone was selected by the program’s Advisory Board as one of just 25 finalists out of 187 shortlisted applicants. “Central nervous system injuries impo ...

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this NovemberTORONTO and HAIFA, Israel, July 25, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that the Falling Walls Foundation has named the Company a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. NurExone was selected by th ...

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States ...

公司战略重组 - 公司宣布战略重组以延长运营资金期限 重点将资源集中于腺相关病毒(AAV)心血管平台 包括Danon病、PKP2相关心律失常性心肌病(PKP2-ACM)和BAG3相关扩张型心肌病(BAG3-DCM)的临床项目 同时提交KRESLADI(原RP-L201)针对严重白细胞粘附缺陷-I型(LAD-I)的完整回复 [1][2] - 此次转型反映了公司对晚期AAV管线的专注 该策略已于2025年1月宣布 [3] - 公司将裁员约30% 结合其他成本节约措施 预计12个月内运营费用减少近25% [3] 财务状况与运营展望 - 公司现有现金资源预计可支持运营至2027年第二季度 [3] - 由于业务和战略重点调整 Fanconi贫血(FA RP-L102)和丙酮酸激酶缺乏症(PKD RP-L301)项目将延迟 RP-L102在2026年获得监管批准的可能性较低 [4] 监管与临床进展 - 5月FDA对公司Danon病研究性基因疗法RP-A501的2期关键试验实施临床暂停 [4] - 公司已完成对KRESLADI(原RP-L201)的完整回复提交 针对严重白细胞粘附缺陷-I型(LAD-I) [2] 分析师观点与市场反应 - 美国银行证券分析师Jason Zemansky将公司评级从买入下调至中性 目标价从9美元降至4美元 [5] - 分析师认为Danon病基因疗法是公司表现的主要驱动力 但近期基因治疗领域的高调失败削弱了投资者信心 [5] - 美国银行指出公司间接承认其主导项目前景在短期内仍不确定 尽管成本节约可能长期有益 但近期收益有限 [6] - 截至周五最后一次检查 RCKT股价下跌2 80%至3 12美元 [6]

行业趋势 - AI驱动的医疗诊断和药物研发正在重塑行业格局 传统制药公司面临创新瓶颈 [2][5] - AI原生企业通过数据架构、基因组学诊断和机器学习加速分子发现 颠覆传统药物开发流程 [1][2][5] - 投资者资金明显向AI医疗领域倾斜 传统制药公司股价表现平淡 [4][5] 公司动态 Palantir Technologies Inc (PLTR) - 公司Foundry平台为医院提供高透明度数据解决方案 推动癌症诊断合作 [1] - 股价本月上涨近10% 年内涨幅更高 市场看好其二季度财报表现 [3] Tempus AI Inc (TEM) - 基因组学诊断技术可缩短药物开发周期数月 当前股价稳定在64美元左右 [2][3] - 尽管近一月回调约6% 投资者仍对其诊断平台保持信心 [3] Recursion Pharmaceuticals Inc (RXRX) - 借助NVIDIA的AI算力 公司分子研发速度远超传统方法 [2] - 股价自6月底上涨近15% 但年内仍下跌约10% 显示市场对其AI药物管线重燃兴趣 [4] 传统制药公司 - Pfizer(PFE)和Merck(MRK)股价分别徘徊在24.7美元和84.49美元 缺乏市场关注 [4] - 面临专利到期、定价监管压力和创新周期放缓等结构性挑战 [4][5] 技术应用 - Palantir构建医疗数据基础设施 Tempus将AI转化为诊断工具 Recursion结合机器学习与分子库加速研发 [5] - AI技术已渗透至药物发现、临床试验设计和临床决策全链条 [5]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...